Zacks Investment Research lowered shares of Celsion (NASDAQ:CLSN) from a hold rating to a sell rating in a research report sent to investors on Wednesday.
According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
A number of other equities research analysts have also issued reports on CLSN. Brookline Capital Management reissued a buy rating on shares of Celsion in a research report on Tuesday, November 20th. ValuEngine raised Celsion from a hold rating to a buy rating in a research report on Thursday, November 1st. Finally, Oppenheimer set a $9.00 target price on Celsion and gave the company a buy rating in a research report on Thursday, November 15th.
Celsion (NASDAQ:CLSN) last announced its earnings results on Thursday, November 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.04). Celsion had a negative net margin of 4,282.33% and a negative return on equity of 104.30%. The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.13 million. As a group, equities research analysts predict that Celsion will post -1.34 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in Celsion by 72.3% in the 2nd quarter. BlackRock Inc. now owns 114,844 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 48,194 shares during the last quarter. Vanguard Group Inc. raised its position in Celsion by 40.9% in the 3rd quarter. Vanguard Group Inc. now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 214,829 shares during the last quarter. Finally, Vanguard Group Inc raised its position in Celsion by 40.9% in the 3rd quarter. Vanguard Group Inc now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 214,829 shares during the last quarter. 6.29% of the stock is currently owned by institutional investors and hedge funds.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.